Mechanism of Action
CXCR4 Blockade and HSC Mobilization
CXCR4 on HSCs binds CXCL12 secreted by bone marrow stromal cells, maintaining HSCs in the marrow niche via integrin activation (VLA-4, LFA-1) and CXCR4-mediated cytoskeletal signaling. Motixafortide competitively blocks CXCL12 binding to CXCR4, preventing this retention signal. Within hours, HSCs detach from the niche and enter the peripheral blood. When combined with G-CSF (which expands HSC numbers and disrupts other niche interactions), the mobilization of CD34+ progenitors is dramatically amplified versus G-CSF alone.
Receptor Pharmacology vs Plerixafor
Plerixafor (AMD3100) is a bicyclam small molecule CXCR4 antagonist with a half-life of ~5 hours requiring daily evening dosing. Motixafortide is a cyclic peptide with a longer half-life (~6 hours) and higher receptor binding affinity. The GENESIS trial showed motixafortide + G-CSF mobilized >3-fold more CD34+ cells per apheresis session than plerixafor + G-CSF, achieving the transplant threshold in far fewer collection sessions.
Anti-Tumor and Immune Effects
CXCR4 is overexpressed in many tumors including AML, breast cancer, and NHL, where CXCL12/CXCR4 signaling promotes tumor cell survival, proliferation, and metastasis to CXCL12-rich niches (bone marrow, liver, lung). Motixafortide's CXCR4 blockade in tumor cells may directly impair tumor survival signaling and disrupt protective niche interactions, with potential anti-tumor activity beyond mobilization. Research programs in AML, MDS, and solid tumors are ongoing.
Research Summary
GENESIS Trial (Pivotal)
Standard of CareThe Phase III GENESIS trial (n=122 multiple myeloma patients) showed motixafortide + G-CSF achieved the CD34+ cell threshold for double autologous transplantation (>6x10^6 cells/kg) in 87.5% of patients versus 9.5% with plerixafor + G-CSF. The median CD34+ yield was 13.5 vs 5.3 million cells/kg. The primary endpoint (proportion collecting >6x10^6 CD34+/kg in up to 2 apheresis sessions) favored motixafortide overwhelmingly.
AML and Oncology
Clinical ResearchIn AML, CXCR4 blockade may sensitize leukemia cells to chemotherapy by disrupting the protective bone marrow niche. Phase I/II trials of motixafortide + cytarabine-based chemotherapy in relapsed/refractory AML showed clinical activity with acceptable tolerability. The concept of "mobilizing" AML blasts from the protective marrow niche to make them chemotherapy-susceptible is being explored in multiple combinations.
HIV Research
ResearchCXCR4 is one of two HIV co-receptors (along with CCR5) used by X4-tropic HIV strains for cell entry. CXCR4 antagonists have theoretical antiviral activity against X4-tropic HIV. Early clinical data on plerixafor in HIV showed transient viral load increases (mobilizing CXCR4-tropic HIV from reservoirs) before reduction, complicating the antiviral approach. Motixafortide's application in HIV eradication strategies (mobilizing latent reservoirs for "kick and kill") is being researched.
Calculate your Motixafortide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Stem cell mobilization (MM) | 1.25 mg/kg SC on each collection day | Once daily for up to 4 consecutive days | SC injection (G-CSF days 1-5 precede first motixafortide dose) |
| CXCR4 blockade (research) | 0.1-10 mcg/mL in cell culture | Acute or continuous exposure | Cell culture medium |
| AML sensitization (clinical trial) | 1.25 mg/kg SC | Days 1-4 of chemo cycle | SC injection with cytarabine |
Always combine with G-CSF for stem cell mobilization. G-CSF given for 4 days before first motixafortide dose. Collection (apheresis) begins ~11 hours after first motixafortide injection.
Interactions
Safety Profile
Motixafortide is generally well-tolerated. Injection site reactions (pain, erythema, pruritus) are very common (~90%), typically mild to moderate and resolving within 24 hours. Flushing (heat sensation) and perioral tingling occur in ~20%. Serious adverse events include hypersensitivity reactions (<1%) - patients should be monitored for 30 minutes post-injection. Vasovagal reactions (dizziness, hypotension upon standing) occur in ~5%. In the GENESIS trial, no new safety signals beyond injection site reactions were identified versus plerixafor. Leukocytosis from G-CSF co-administration is expected and managed by dose adjustment.
References
- [1]Calandra G, et al. Motixafortide (BL-8040) plus G-CSF to mobilize hematopoietic stem cells for autologous transplantation in myeloma: Phase 3 GENESIS trial. Bone Marrow Transplant. 2023.
- [2]Peled A, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer. Sci Transl Med. 2020.
- [3]Lapidot T, et al. How do stem cells find their way home? Blood. 2005.